Stat3 is a member of the signal transducers and activators of transcription (STAT) protein family that has been shown to be essential for embryonic development and to be activated within cells by a variety of soluble mediators and where it contributes to multiple cell fate decisions including proliferation and differentiation. Using both antisense and dominant negative strategies, Stat3 was shown to be required for TGF-alpha/EGFR- mediated autocrine proliferation of squamous cell carcinoma of the head and neck (SCCHN) cells as well as G-CSF-induced differentiation of murine myeloid cells. Stat3 is recruited to receptor complexes through Stat3 SH2 binding to phosphotyrosine motifs including the consensus motif YXXQ identified within many receptors including the EGFR (at Y1068 and Y1086) and the G-CSFR (at Y704) and to the phosphotyrosine motif YXXC identified thus far only within the G-CSFR (at Y744). Comparison of the Stat3 SH2 domain with non-STAT SH2 domains of known structure revealed the greatest overall homology with v-Src SH2 domain. The pocket within the v-Src SH2 that binds the +3 residue within phosphotyrosine ligands is hydrophobic and preferentially binds phosphotyrosine ligands containing hydrophobic residues at the +3 site. In contrast, modeling of this pocket within the Stat3 SH2 using the recently reported structure of Statl as a template reveals polar residues at the critical sites interacting with the +3 residue of the phosphotyrosine ligand which is consistent with the observations that the preferred phosphotyrosine ligands for Stat3 SH2 are YXXQ and YXXC which feature polar amino acid residues (Q and C) at the +3 position. The validity of this model will be tested in vitro and in vivo in order to understand in greater molecular detail the basis for the Stat3 SH2-phosphotyrosine interaction. The long term goal of these studies is to develop peptidomimetics capable of altering Stat3 interaction with the EGFR and G-CSFR and thereby inhibit SCCHN proliferation and promoting acute myeloid cell differentiation. Towards this end, the Specific Aims of this proposal are: I. To examine the molecular determinants for Stat3 SH2 binding to the phosphotyrosine ligands of the G-CSF and EGF receptors. II. To determine the contribution of the Stat3 SH2-phosphotyrosine binding to G-CSF-induced myeloid differentiation and TGF-alpha/EGFR-mediated SCCHN proliferation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA086430-05
Application #
6633746
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Mufson, R Allan
Project Start
1999-09-01
Project End
2005-06-30
Budget Start
2003-07-01
Budget End
2005-06-30
Support Year
5
Fiscal Year
2003
Total Cost
$299,019
Indirect Cost
Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Redell, Michele S; Tsimelzon, Anna; Hilsenbeck, Susan G et al. (2007) Conditional overexpression of Stat3alpha in differentiating myeloid cells results in neutrophil expansion and induces a distinct, antiapoptotic and pro-oncogenic gene expression pattern. J Leukoc Biol 82:975-85
Qiu, Jihui; Huang, Ying; Chen, Guoqiang et al. (2007) Aberrant chromatin remodeling by retinoic acid receptor alpha fusion proteins assessed at the single-cell level. Mol Biol Cell 18:3941-51
Shao, Huang; Xu, Xuejun; Jing, Naijie et al. (2006) Unique structural determinants for Stat3 recruitment and activation by the granulocyte colony-stimulating factor receptor at phosphotyrosine ligands 704 and 744. J Immunol 176:2933-41
Jing, Naijie; Zhu, Qiqing; Yuan, Ping et al. (2006) Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol Cancer Ther 5:279-86
Jing, Naijie; Sha, Wei; Li, Yidong et al. (2005) Rational drug design of G-quartet DNA as anti-cancer agents. Curr Pharm Des 11:2841-54
Jing, Naijie; Tweardy, David J (2005) Targeting Stat3 in cancer therapy. Anticancer Drugs 16:601-7
Dong, Shuo; Stenoien, David L; Qiu, Jihui et al. (2004) Reduced intranuclear mobility of APL fusion proteins accompanies their mislocalization and results in sequestration and decreased mobility of retinoid X receptor alpha. Mol Cell Biol 24:4465-75
Shao, Huang; Xu, Xuejun; Mastrangelo, Mary-Ann A et al. (2004) Structural requirements for signal transducer and activator of transcription 3 binding to phosphotyrosine ligands containing the YXXQ motif. J Biol Chem 279:18967-73
Jing, Naijie; Li, Yidong; Xiong, Weijun et al. (2004) G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res 64:6603-9
Shao, Huang; Cheng, Haiyun Y; Cook, Richard G et al. (2003) Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res 63:3923-30

Showing the most recent 10 out of 14 publications